Ranbaxy Leadership Casestudy
Ranbaxy Laboratories Limited is an Indian multinational pharmaceutical company that was incorporated in India in 1961. The company went public in 1973 and Japanese pharmaceutical company Daiichi Sankyo acquired a controlling share in 2008. Ranbaxy exports its products to 125 countries with ground operations in 43 and manufacturing facilities in eight countries. In 2011, Ranbaxy Global Consumer Health Care received the OTC Company of the year award. Ranbaxy is a true pioneer among Indian companies, in terms of globalization. The company's entry into global markets has been a proactive, well-planned effort. Ranbaxy's attempts to globalize received a major boost when Dr. Parvinder Singh took over as Chairman and MD in 1993 from his father, Bhai Mohan Singh. Dr. Parvinder decided to remain focused on the pharmaceuticals business. But he realized he had to find new markets. He was confident that Ranbaxy could use its core strengths to tap global markets. Dr. Parvinder articulated the company's mission of becoming a research-based international company. By the late 1990s, Ranbaxy had successfully penetrated several overseas markets, including Russia, China, US and several European countries. By 2000, Ranbaxy was generating almost 50% of its sales outside India. After the demise of Dr. Parvinder, DS Brar, the new CEO had given a fresh impetus to the globalization process. DS Brar is a success story of Ranbaxy who has taken the company closer to its vision. He joined the company in 1977 as a business development manager and since then there has been no looking back. He took over reigns from Dr. Parvinder from the year 1999 and became the CEO of the company. Though he never really had the support of the Singh family, he stayed focussed and directed all his actions towards the goal he had set for the company. Ranbaxy saw a turning point under his leadership when he transformed it into a ‘research based international pharmaceutical company’,